Figure 1





100
80
60
40
20
0
Percent survival
<15 positive antibodies
>15 positive antibodies
0
5
10
15
20
Survival post-treatment (months)

Figure 2



Deceased **Alive**

Figure 3








Figure 4

(months)	0	1	4	6
	G0	G2	G3	G6
BRAF	0.335	0.275	0.229	0.265
CABYR	0.52	0.437	0.435	0.166
CRISP3	0.237	0.252	0.255	0.277
CSAG2	0.194	0.185	0.261	0.304
CTAG2	0.327	0.266	0.284	0.471
DHFR	0.467	0.221	0.287	0.225
FHLT17	0.416	0.34	0.411	0.205
GAGE1	0.284	0.204	0.295	0.35
LDHC	0.254	0.168	0.171	0.224
MAGEA1	0.496	0.39	0.383	0.265
MAGEA3	0.374	0.281	0.507	0.191
MAGEA4	0.347	0.27	0.37	0.257
MAGEB6	0.354	0.268	0.322	0.24
MAPK1	0.439	0.294	0.347	0.175
MICA	0.363	0.33	0.332	0.288
MUC1	0.41	0.26	0.308	0.274
NLRP4	0.506	0.298	0.481	0.273
NYESO1	0.453	0.445	0.507	0.209
P53	0.367	0.26	0.409	0.239
PBK	0.405	0.307	0.411	0.221
PRAME	0.271	0.285	0.352	0.268
SOX2	0.355	0.169	0.333	0.254
SPANXA1	0.357	0.319	0.284	0.27
SSX2	0.432	0.417	0.418	0.212
SSX4	0.306	0.21	0.302	0.275
SSX5	0.431	0.368	0.433	0.254
TSGA10	0.315	0.182	0.325	0.232
TSSK6	0.388	0.327	0.32	0.231
TULP2	0.302	0.29	0.367	0.253
XAGE2	0.393	0.318	0.476	0.344
ZNF165	0.434	0.342	0.461	0.275
SCORE	0	0	0	0

Patient G (26 months, alive)

	0	1	3	4
	I0	I2	I2.5	I3
BRAF	0.34	0.387	0.875	0.804
CABYR	0.612	0.762	0.545	0.632
CRISP3	0.377	0.403	0.562	0.697
CSAG2	0.299	0.324	0.481	0.618
CTAG2	0.491	0.569	0.938	0.927
DHFR	0.411	0.51	0.658	0.753
FHLT17	0.569	0.654	0.678	0.883
GAGE1	0.345	0.378	0.687	0.763
LDHC	0.275	0.289	0.593	0.628
MAGEA1	0.649	0.739	0.581	0.709
MAGEA3	0.603	0.71	0.72	0.776
MAGEA4	0.519	0.614	0.737	0.747
MAGEB6	0.651	0.713	0.625	0.69
MAPK1	0.579	0.599	0.706	0.789
MICA	0.412	0.424	0.594	0.872
MUC1	0.546	0.494	0.559	0.615
NLRP4	0.755	0.767	0.747	0.815
NYESO1	0.774	0.759	0.666	0.696
P53	0.579	0.787	0.545	0.608
PBK	0.609	0.759	0.679	0.832
PRAME	0.465	0.562	0.721	0.765
SOX2	0.381	0.496	0.66	0.804
SPANXA1	0.47	0.622	0.649	0.796
SSX2	0.631	0.745	0.623	0.737
SSX4	0.393	0.537	0.609	0.728
SSX5	0.681	0.768	0.625	0.784
TSGA10	0.54	0.748	0.689	0.793
TSSK6	0.525	0.622	0.617	0.7
TULP2	0.461	0.627	0.686	0.793
XAGE2	0.584	0.684	0.592	0.611
ZNF165	0.603	0.867	0.693	0.736
SCORE	10	18	22	31

Patient I (6 months, deceased)

Figure 5




1.2
1.1
1
0.9
0.8
0.7
0.6
BRAF
CABYR
CRISP3
CSAG2
CTAG2
DHFR
FHLT17
GAGE1
LDHC
MAGEA1
MAGEA3
MAGEA4
MAGEB6
MAPK1
MICA
MUC1
NLRP4
NYESO1
P53
PBK
PRAME
SOX2
SPANXA1
SSX2
SSX4
SSX5
TSGA10
TSSK6
TULP2
XAGE2
ZNF165
6mo.
4mo
1mo.
Pre-treat.
4mo.
3mo
1mo.
Pre-treat.


Figure 6



10/18/2011 10/26/2011 11/29/2011




1/7/2012



2/8/2012

Figure 7



Note: Patients 12A and 33A had imaging complete responses